Adverse events of raltegravir and dolutegravir
| Autor: | Huldrych F. Günthard, Manuel Battegay, Enos Bernasconi, Stefan Erb, Alexandra Calmy, Pietro Vernazza, L Elzi, Hansjakob Furrer, Matthias Cavassini |
|---|---|
| Přispěvatelé: | Swiss HIV Cohort Study Group |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male HIV Infections neuropsychiatric adverse events Piperazines Drug-Related Side Effects and Adverse Reactions/epidemiology chemistry.chemical_compound 0302 clinical medicine Heterocyclic Compounds 80 and over Anti-HIV Agents/administration & dosage/adverse effects Immunology and Allergy 030212 general & internal medicine Prospective Studies Prospective cohort study ddc:616 Aged 80 and over Mental Disorders Hazard ratio Middle Aged Mental Disorders/chemically induced/epidemiology 3. Good health dolutegravir Infectious Diseases Dolutegravir Female raltegravir Heterocyclic Compounds 3-Ring Switzerland medicine.drug Cohort study Adult medicine.medical_specialty Adolescent Drug-Related Side Effects and Adverse Reactions Anti-HIV Agents Pyridones 030106 microbiology Immunology HIV Infections/drug therapy 610 Medicine & health 03 medical and health sciences Young Adult Raltegravir Potassium/administration & dosage/adverse effects Internal medicine Raltegravir Potassium Aged Anti-HIV Agents/administration & dosage Anti-HIV Agents/adverse effects Heterocyclic Compounds 3-Ring/administration & dosage Heterocyclic Compounds 3-Ring/adverse effects Humans Mental Disorders/chemically induced Mental Disorders/epidemiology Raltegravir Potassium/administration & dosage Raltegravir Potassium/adverse effects Withholding Treatment Oxazines medicine Adverse effect business.industry HIV toxicity Raltegravir Surgery Discontinuation Regimen chemistry Clinical Science: Concise Communications 3-Ring/administration & dosage/adverse effects business |
| Zdroj: | Elzi, Luigia; Erb, Stefan; Furrer, Hansjakob; Cavassini, Matthias; Calmy, Alexandra; Vernazza, Pietro; Günthard, Huldrych; Bernasconi, Enos; Battegay, Manuel (2017). Adverse events of raltegravir and dolutegravir. AIDS, 31(13), pp. 1853-1858. Lippincott Williams & Wilkins 10.1097/QAD.0000000000001590 AIDS, vol. 31, no. 13, pp. 1853-1858 AIDS (London, England) AIDS, Vol. 31, No 13 (2017) pp. 1853-1858 |
| ISSN: | 0269-9370 |
| DOI: | 10.1097/QAD.0000000000001590 |
| Popis: | OBJECTIVE To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. DESIGN Prospective cohort study. METHODS All antiretroviral therapy (ART)-naive and ART-experienced HIV-infected individuals from the Swiss HIV Cohort Study who initiated raltegravir or dolutegravir between 2006 and 2015 were investigated concerning treatment modification within the first year. RESULTS Of 4041 patients initiating ART containing raltegravir (n = 2091) or dolutegravir (n = 1950), 568 patients discontinued ART during the first year, corresponding to a rate of 15.5 [95% confidence interval (CI) 14.5-16.9] discontinuations per 100 patient-years. Only 10 patients on raltegravir (0.5%) and two patients on dolutegravir (0.1%) demonstrated virologic failure. The main reason for ART discontinuation was convenience expressed as patient's wish, physician's decision, or treatment simplification (n = 302). Toxicity occurred in 4.3% of patients treated with raltegravir and 3.6% with dolutegravir, respectively. In multivariable analysis, the only independent risk factor for discontinuing ART because of toxicity was female sex (hazard ratio 1.98, 95% CI 1.45-2.71, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|